Advanced Bitcoin Technologies AG Q2 FY2023 Earnings Call

· Earnings call transcript and AI-powered summary

Financial Highlights
  • Adjusted EPS: $1.08, reflecting a solid contribution from the company’s core business.
  • Organic Sales Growth (excluding COVID testing): +11.5% YoY, marking the second consecutive quarter of low double-digit growth.
  • Total sales (including COVID testing): -9.2% YoY due to expected COVID-related sales decline.
  • Foreign Exchange Impact: -2.5% on total sales due to a stronger U.S. dollar.
Segment Performance vs. Q2 2022
  • Nutrition: +10% growth overall; U.S. Pediatric Nutrition up 20%+ as Abbott regains ~75% of infant formula market share lost in 2022 due to recall.
  • Established Pharmaceuticals: +12.5% organic growth, driven by India, China, and key therapeutic areas (gastroenterology, women's health, CNS).
  • Diagnostics (ex-COVID): +7% growth, led by Core Lab (+10%) in U.S., Europe, and China. Blood transfusion testing recovered post-pandemic.
  • Medical Devices: +14% organic growth. Notably:
    • FreeStyle Libre: $1.3B in revenue (+25% YoY)
    • Electrophysiology: +17% (U.S. +9%, international +24%), strong demand and TactiFlex catheter approval

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning, and thank you for standing by. Welcome to Abbott's Second Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Mike Comilla, Vice President of Relations. Michael Comilla: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer. Robert and Bob will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2023. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2022. Abbott undertakes no obligation to release publi

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional